Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 104,926
  • Shares Outstanding, K 18,571
  • Annual Sales, $ 710 K
  • Annual Income, $ -36,490 K
  • 60-Month Beta 2.06
  • Price/Sales 151.44
  • Price/Cash Flow N/A
  • Price/Book 1.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.65
  • Number of Estimates 3
  • High Estimate -0.64
  • Low Estimate -0.66
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -14.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.27 +7.21%
on 05/15/19
7.50 -24.67%
on 04/22/19
-1.94 (-25.56%)
since 04/18/19
3-Month
5.27 +7.21%
on 05/15/19
8.24 -31.46%
on 04/10/19
-0.35 (-5.83%)
since 02/21/19
52-Week
3.66 +54.37%
on 01/02/19
10.42 -45.78%
on 05/22/18
-4.40 (-43.78%)
since 05/21/18

Most Recent Stories

More News
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Alpine Immune Sciences, Inc., Seattle, WA, (NASDAQ:ALPN), a leading immunotherapy company focused on developing...

ALPN : 5.65 (-1.73%)
ADAP : 3.92 (+8.29%)
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results

--Completed financing to fund further development of both lead programs

ALPN : 5.65 (-1.73%)
Earnings Preview: Alpine Immune Sciences (ALPN) Q1 Earnings Expected to Decline

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALPN : 5.65 (-1.73%)
Alpine Immune Sciences Appoints Stanford Peng to President and Head of Research and Development

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) ("Alpine"), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and...

ALPN : 5.65 (-1.73%)
The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

The Zacks Analyst Blog Highlights: CMS Energy, Alpine Immune Sciences, Kohl's, Franklin Resources and Dominion Energy

D : 76.73 (+0.89%)
ALPN : 5.65 (-1.73%)
CMS : 56.35 (-0.65%)
BEN : 33.73 (+1.20%)
KSS : 55.15 (-12.34%)
5 Best Stocks to Buy Ahead of Q1 Earnings Season

Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016. Revenues are expected to rise 4.6%.

D : 76.73 (+0.89%)
WFC : 46.33 (+1.94%)
JPM : 111.73 (+0.34%)
ALPN : 5.65 (-1.73%)
CMS : 56.35 (-0.65%)
BEN : 33.73 (+1.20%)
KSS : 55.15 (-12.34%)
Will Nivalis Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.

ALPN : 5.65 (-1.73%)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

ALPN : 5.65 (-1.73%)
OTIC : 2.67 (unch)
MTEM : 7.49 (-1.71%)
TCDA : 37.26 (+2.93%)
ATNM : 0.30 (-2.56%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 23.43 (+1.69%)
ACRX : 2.96 (+3.50%)
ALPN : 5.65 (-1.73%)
OTIC : 2.67 (unch)
MTEM : 7.49 (-1.71%)
TCDA : 37.26 (+2.93%)
ATNM : 0.30 (-2.56%)
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results

--Completed $25 Million Private Placement

ALPN : 5.65 (-1.73%)
GILD : 66.52 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade ALPN with:

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

2nd Resistance Point 5.85
1st Resistance Point 5.75
Last Price 5.65
1st Support Level 5.57
2nd Support Level 5.50

See More

52-Week High 10.42
Fibonacci 61.8% 7.84
Fibonacci 50% 7.04
Fibonacci 38.2% 6.24
Last Price 5.65
52-Week Low 3.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar